Cargando…

Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function

Dysregulation of dopaminergic transmission induced by the HIV-1 transactivator of transcription (Tat) has been implicated as a central factor in the development of HIV-1 associated neurocognitive disorders (HAND). We have demonstrated that the tyrosine470 residue of the human dopamine transporter (h...

Descripción completa

Detalles Bibliográficos
Autores principales: Strauss, Matthew J., Porter, Katherine D., Quizon, Pamela M., Davis, Sarah E., Lin, Steven, Yuan, Yaxia, Martinez-Muniz, Gustavo A., Sun, Wei-Lun, Zhan, Chang-Guo, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518868/
https://www.ncbi.nlm.nih.gov/pubmed/36170295
http://dx.doi.org/10.1371/journal.pone.0275182
_version_ 1784799279062188032
author Strauss, Matthew J.
Porter, Katherine D.
Quizon, Pamela M.
Davis, Sarah E.
Lin, Steven
Yuan, Yaxia
Martinez-Muniz, Gustavo A.
Sun, Wei-Lun
Zhan, Chang-Guo
Zhu, Jun
author_facet Strauss, Matthew J.
Porter, Katherine D.
Quizon, Pamela M.
Davis, Sarah E.
Lin, Steven
Yuan, Yaxia
Martinez-Muniz, Gustavo A.
Sun, Wei-Lun
Zhan, Chang-Guo
Zhu, Jun
author_sort Strauss, Matthew J.
collection PubMed
description Dysregulation of dopaminergic transmission induced by the HIV-1 transactivator of transcription (Tat) has been implicated as a central factor in the development of HIV-1 associated neurocognitive disorders (HAND). We have demonstrated that the tyrosine470 residue of the human dopamine transporter (hDAT) plays a critical role in Tat-hDAT interaction. Based on the computational modeling predictions, the present study sought to examine the mutational effects of the tyrosine467 residue of the human norepinephrine transporter (hNET), a corresponding residue of the hDAT tyrosine470, on Tat-induced inhibition of reuptake of dopamine through the hNET. Mutations of the hNET tyrosine467 to a histidine (Y467H) or a phenylalanine (Y467F) displayed similar kinetic properties of reuptake of [(3)H]dopamine and [(3)H]norepinephrine in PC12 cells expressing wild-type hNET and its mutants. Compared to wild-type hNET, neither of Y467H or Y467F altered B(max) and K(d) values of [(3)H]WIN35,428 binding, whereas Y467H but not Y467F decreased the B(max) of [(3)H]nisoxetine binding without changes in K(d). Y467H also increased the affinity of nisoxetine for inhibiting [(3)H]dopamine uptake relative to wild-type hNET. Recombinant Tat(1-86) (140 nM) induced a significant reduction of [(3)H]dopamine uptake in wild-type hNET, which was attenuated in both Y467H and Y467F. Compared to wild-type hNET, neither Y467H or Y467F altered [(3)H]dopamine efflux in CHO cells expressing WT hNET and mutants, whereas Y467F but not Y467H decreased [(3)H]MPP(+) efflux. These results demonstrate tyrosine467 as a functional recognition residue in the hNET for Tat-induced inhibition of dopamine transport and provide a novel insight into the molecular basis for developing selective compounds that target Tat-NET interactions in the context of HAND.
format Online
Article
Text
id pubmed-9518868
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-95188682022-09-29 Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function Strauss, Matthew J. Porter, Katherine D. Quizon, Pamela M. Davis, Sarah E. Lin, Steven Yuan, Yaxia Martinez-Muniz, Gustavo A. Sun, Wei-Lun Zhan, Chang-Guo Zhu, Jun PLoS One Research Article Dysregulation of dopaminergic transmission induced by the HIV-1 transactivator of transcription (Tat) has been implicated as a central factor in the development of HIV-1 associated neurocognitive disorders (HAND). We have demonstrated that the tyrosine470 residue of the human dopamine transporter (hDAT) plays a critical role in Tat-hDAT interaction. Based on the computational modeling predictions, the present study sought to examine the mutational effects of the tyrosine467 residue of the human norepinephrine transporter (hNET), a corresponding residue of the hDAT tyrosine470, on Tat-induced inhibition of reuptake of dopamine through the hNET. Mutations of the hNET tyrosine467 to a histidine (Y467H) or a phenylalanine (Y467F) displayed similar kinetic properties of reuptake of [(3)H]dopamine and [(3)H]norepinephrine in PC12 cells expressing wild-type hNET and its mutants. Compared to wild-type hNET, neither of Y467H or Y467F altered B(max) and K(d) values of [(3)H]WIN35,428 binding, whereas Y467H but not Y467F decreased the B(max) of [(3)H]nisoxetine binding without changes in K(d). Y467H also increased the affinity of nisoxetine for inhibiting [(3)H]dopamine uptake relative to wild-type hNET. Recombinant Tat(1-86) (140 nM) induced a significant reduction of [(3)H]dopamine uptake in wild-type hNET, which was attenuated in both Y467H and Y467F. Compared to wild-type hNET, neither Y467H or Y467F altered [(3)H]dopamine efflux in CHO cells expressing WT hNET and mutants, whereas Y467F but not Y467H decreased [(3)H]MPP(+) efflux. These results demonstrate tyrosine467 as a functional recognition residue in the hNET for Tat-induced inhibition of dopamine transport and provide a novel insight into the molecular basis for developing selective compounds that target Tat-NET interactions in the context of HAND. Public Library of Science 2022-09-28 /pmc/articles/PMC9518868/ /pubmed/36170295 http://dx.doi.org/10.1371/journal.pone.0275182 Text en © 2022 Strauss et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Strauss, Matthew J.
Porter, Katherine D.
Quizon, Pamela M.
Davis, Sarah E.
Lin, Steven
Yuan, Yaxia
Martinez-Muniz, Gustavo A.
Sun, Wei-Lun
Zhan, Chang-Guo
Zhu, Jun
Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function
title Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function
title_full Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function
title_fullStr Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function
title_full_unstemmed Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function
title_short Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function
title_sort mutations of tyrosine 467 in the human norepinephrine transporter attenuate hiv-1 tat-induced inhibition of dopamine transport while retaining physiological function
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518868/
https://www.ncbi.nlm.nih.gov/pubmed/36170295
http://dx.doi.org/10.1371/journal.pone.0275182
work_keys_str_mv AT straussmatthewj mutationsoftyrosine467inthehumannorepinephrinetransporterattenuatehiv1tatinducedinhibitionofdopaminetransportwhileretainingphysiologicalfunction
AT porterkatherined mutationsoftyrosine467inthehumannorepinephrinetransporterattenuatehiv1tatinducedinhibitionofdopaminetransportwhileretainingphysiologicalfunction
AT quizonpamelam mutationsoftyrosine467inthehumannorepinephrinetransporterattenuatehiv1tatinducedinhibitionofdopaminetransportwhileretainingphysiologicalfunction
AT davissarahe mutationsoftyrosine467inthehumannorepinephrinetransporterattenuatehiv1tatinducedinhibitionofdopaminetransportwhileretainingphysiologicalfunction
AT linsteven mutationsoftyrosine467inthehumannorepinephrinetransporterattenuatehiv1tatinducedinhibitionofdopaminetransportwhileretainingphysiologicalfunction
AT yuanyaxia mutationsoftyrosine467inthehumannorepinephrinetransporterattenuatehiv1tatinducedinhibitionofdopaminetransportwhileretainingphysiologicalfunction
AT martinezmunizgustavoa mutationsoftyrosine467inthehumannorepinephrinetransporterattenuatehiv1tatinducedinhibitionofdopaminetransportwhileretainingphysiologicalfunction
AT sunweilun mutationsoftyrosine467inthehumannorepinephrinetransporterattenuatehiv1tatinducedinhibitionofdopaminetransportwhileretainingphysiologicalfunction
AT zhanchangguo mutationsoftyrosine467inthehumannorepinephrinetransporterattenuatehiv1tatinducedinhibitionofdopaminetransportwhileretainingphysiologicalfunction
AT zhujun mutationsoftyrosine467inthehumannorepinephrinetransporterattenuatehiv1tatinducedinhibitionofdopaminetransportwhileretainingphysiologicalfunction